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Background: Interest in the measurement of health related quality of life and psychosocial functioning from the
patient’s perspective in diabetes mellitus has grown in recent years. The aim of this study is to investigate the
psychometric performance of and agreement between the generic EQ-5D and SF-6D and diabetes specific DHP-18
in Type 2 diabetes. This will support the future use of the measures by providing further evidence regarding their
psychometric properties and the conceptual overlap between the instruments. The results will inform whether
the measures can be used with confidence alongside each other to provide a more holistic profile of people with
Type 2 diabetes.
Methods: A large longitudinal dataset (n = 1,184) of people with Type 2 diabetes was used for the analysis.
Convergent validity was tested by examining correlations between the measures. Known group validity was
tested across a range of clinical and diabetes severity indicators using ANOVA and effect size statistics.
Agreement was examined using Bland-Altman plots. Responsiveness was tested by examining floor and ceiling
effects and standardised response means.
Results: Correlations between the measures indicates that there is overlap in the constructs assessed (with
correlations between 0.1 and 0.7 reported), but there is some level of divergence between the generic and condition
specific instruments. Known group validity was generally good but was not consistent across all indicators included
(with effect sizes from 0 to 0.74 reported). The EQ-5D and SF-6D displayed a high level of agreement, but there was
some disagreement between the generic measures and the DHP-18 dimensions across the severity range.
Responsiveness was higher in those who self-reported change in health (SRMs between 0.06 and 0.25).
Conclusions: The psychometric assessment of the relationship between the EQ-5D, SF-6D and DHP-18 shows that all
have a level of validity for use in Type 2 diabetes. This suggests that the measures can be used alongside each other to
provide a more holistic assessment of with the quality of life impacts of Type 2 diabetes.
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Interest in the measurement of health related quality
of life (HRQL) and psychosocial functioning from the
patient’s perspective in diabetes mellitus has grown in
recent years. Diabetes is a chronic disease with a range
of related health complications including heart disease,
stroke, and kidney, feet and eye complications. Type 2* Correspondence: b.mulhern@sheffield.ac.uk
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article, unless otherwise stated.diabetes generally occurs in later life and is caused when
the body does not produce enough insulin. Health con-
cerns related to Type 2 diabetes impact on an individual’s
level of HRQL, including mental health [1,2] and social
activities [3]. Assessing HRQL in diabetes alongside re-
lated clinical factors therefore allows the impact of the
condition and different treatments on areas of health and
functioning that are important to the person with diabetes
to be measured. Both generic and diabetes specific patient
reported outcome measures (PROMS) can be used, and
administering generic and condition specific measuresed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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impacts of diabetes. However to ensure valid and reliable
measurement, it is important to investigate the psycho-
metric performance of both generic and condition specific
measures of health status in diabetes, and also explore the
relationship between instruments.
Generic preference based measures (GPBMs) such as
EQ-5D [4,5] and SF-6D [6,7] can be used in diabetes to
measure health status and HRQL. GPBMs can also be
used in the economic evaluation of interventions using
the Quality Adjusted Life Year (QALY) as the outcome
measure. QALYs combine values for quality and length
of life into a single figure. GPBMs are scored using a
utility scale (that is the quality weight of the QALY)
which is derived by asking the general population to
provide preferences for health states defined by the de-
scriptive system of the measure. This is used to model
utility value for every health state anchored on a 1 (full
health) to 0 (dead) scale (where negative values are
equivalent to states valued as worse than dead). A condi-
tion specific PROM that can be used to assess the rela-
tionship between Type 2 diabetes and psychosocial
functioning is the Diabetes Health Profile [8]. The DHP-
18 has been adopted by the Department of Health for
their Long Term Conditions Patient Reported Outcome
Measures PROMs pilot [9].
The generic nature of the EQ-5D and SF-6D means
that it is important to assess the conditions in which the
measures perform well. There is some evidence to sug-
gest that the EQ-5D is valid for use in Type 2 diabetes.
In a recent review, Janssen and colleagues [10] found
evidence for the construct validity and responsiveness to
change of the EQ-5D, but there was also the suggestion
of the ceiling effect. Kontodimopoulos and colleagues
[11] found that the EQ-5D and SF-6D were sensitive to
a number of diabetes related complications. Meadows
et al. [8] found evidence for the construct validity and
patient acceptability of the DHP-18 for use in Type 2
diabetes, but further evidence regarding responsiveness
to change in health status is required.
Although some evidence exists about the psychometric
properties of the measures, it is important to assess this
across multiple samples, and further work is required to
provide a wider range of evidence for the measures, par-
ticularly in relation to each other. Therefore the aim of
this study is to investigate the construct validity and
responsiveness of the EQ-5D, SF-6D and DHP-18 in a
large sample of people with Type 2 diabetes, and also to
compare the measures. This will support the future use
of the measures by providing further evidence regarding
their psychometric performance. The future use of these
measures is desirable, as the DHP-18 has been tested as
part of the UK Department of Health’s Long Term
Conditions PROMs pilot, and there is interest in usingPROMs in long term conditions to track patient change
(both clinically and for the individual), and assess service
performance. There is also an ongoing need to use
GPBMs for the economic evaluation of interventions,
and use of the EQ-5D in particular is widespread in
population and health surveys. The results will also help
to establish whether the measures are valid, and can
therefore be used with confidence alongside each other
to provide complementary information that allows for a
more detailed picture of the HRQL of people with Type
2 diabetes to be gained. This in turn can inform clinical
decision making. The results regarding the EQ-5D and
SF-6D can also potentially improve confidence in the





The EQ-5D [4,5] is a widely used generic preference
based measure that assesses health status across five
dimensions (mobility, self care, usual activities, pain/
discomfort, anxiety/depression) with three response levels
(therefore generating 243 (35) health states in total). The
utility scale for use in economic evaluation was derived
using the preference elicitation technique Time Trade Off
and ranges from −0.584 to 1.00. A Visual Analogue Scale
(VAS) can also be part of the EQ-5D system, but is not
included in this analysis. The EQ-5D is the measure
recommended for use in the cost utility analysis of new
interventions and treatments by the UK National Institute
for Health and Care Excellence [12].
SF-6D
The SF-6D [6,7] is a generic preference based measure
derived from SF-36/SF-12 that assesses health on six di-
mensions (physical functioning, role functioning, social
functioning, pain, mental health, vitality) with four to six
response options (thereby describing 18,000 health states).
It generates a preference based utility scale (range 0.29
to 1) that was derived using the preference elicitation
technique Standard Gamble. SF-6D is accepted by reim-
bursement agencies in Australia [13] and Canada [14].
DHP-18
The DHP-18 [8] was developed from the DHP-1 [15]
and assesses psychosocial functioning in Type 2 diabetes
across three dimensions: Psychological Distress (PD; 6
items); Barriers to Activity (BA; 7 items); Disinhibited
Eating (DE; 5 items). Each of the 18 items is scored on a
0 to 3 scale (never, sometimes, usually, always), and di-
mensions rescored on a 0–100 scale by dividing the raw
score for each dimension by the overall score range, and
multiplying this by 100. High scores are indicative of
Table 1 Background characteristics
Demographic category N (%)
N 1184














Length of time with diabetes
< 5 years 612 (51.7)






Diabetes related complications None 710 (61.3)




Other health complications None 216 (18.5)
One or more 952 (81.5)
Arthritis 503 (43.2)
Hypertension 513 (44.1)
High cholesterol 588 (50.5)
Heart conditions 108 (11.4)
Depression/anxiety 207 (17.8)
EQ-5D index score 0.652 (0.32)
SF-6D index score 0.693 (0.16)
DHP-18 PD 17.93 (20.5)
BA 21.53 (19.31)
DE 35.93 (23.04)
Change in health baseline-follow up
Health improvement 186 (15.9)
No change 717 (61.7)
Health deterioration 260 (22.4)
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settings including clinical trials and population health
surveys [16-19]. It has been translated to 29 languages
and can be completed using a range of media including
face to face, paper and pencil, and internet or mobile
versions.
Sample
The sample was taken from a longitudinal dataset (base-
line and 1 year follow up) from a UK community-based
postal survey of people with Type 2 diabetes in one local
health board area [18]. The aim of the study was to
investigate the HRQL of the population with diabetes
following service restructuring. Respondents were identi-
fied from primary care diabetes patient registers, and 13
of 19 General Practitioner practices in the area agreed to
take part in the study. Those over 18 who were not
pregnant were included. In total, 4,040 people with both
Type 1 and Type 2 diabetes were approached to take
part in the study, with 1,613 (40%) people with Type 2
diabetes responding at baseline and 1,184 (29%)
responding at follow up. In this study, the 1,184 people
who responded at both time points were included to
allow for the same sample to be used across all analyses.
Table 1 provides the demographic characteristics of this
sample.. It was found that no specific group of diabetics
were prone to non-response at follow up [18]. Missing
data rates were low at baseline (1%-2% for all measures)
and follow up (3%-5%). Missing data was not imputed
for the EQ-5D, SF-6D or DHP-18 as missing data rates
were low. Furthermore t is recommended that missing
DHP-18 data is not imputed when testing the psycho-
metrics of the measure [20].
The majority of the sample (60%) were male, and aged
over 60 years old (72%). The length of time respondents
has been diagnosed with diabetes ranged from 1 week to
51 years, with 52% being diagnosed less than 5 years.
Diabetes management regimes included diet only (27%),
tablets (60%) and insulin (12.5%). At baseline, 38.7% re-
ported diabetes related health complications (including
complications of the feet, eyes and kidneys) and 80.4%
reported other health complications (including arthritis,
hypertension, high cholesterol heart conditions and de-
pression/anxiety). Between baseline and follow up, the
majority of the sample (62%) reported no change in gen-
eral health status, with 16% reporting improvement and
22% reporting deterioration.
Psychometric analysis
A range of psychometric tests were carried out to
assess the construct validity and responsiveness of
the measures in relation to each other and across
different clinical and severity indicators, and these
are described below.
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Construct validity assesses how well an instrument
measures what it was intended to measure. Two types of
construct validity, defined as convergent and known
group validity, were assessed. It should be noted that
there is no gold standard for the measurement of out-
comes in diabetes, and this is due to the heterogeneous
impacts of the condition on HRQL and psychosocial
functioning. Therefore the psychometric validity of in-
struments in relation to each other and to external clin-
ical indicators can only be implied rather than proved.Convergent validity
Convergent validity assesses the relationship between
measures in terms of whether they are measuring over-
lapping constructs (in this case health status and HRQL
as measured by the generic measures and psychological
and behavioural functioning as measured by the DHP-18).
The convergence between the GPBM utility and di-
mension scores and the rescaled DHP-18 dimension
scores was assessed using Pearson’s correlation coef-
ficients. High correlations (where correlations ≥0.7
are strong, <0.7 to ≥0.3 are moderate and <0.3 are
weak) indicates that the measures are assessing simi-
lar diabetes-related constructs.Known group validity
Known group validity assesses the extent to which the
EQ-5D, SF-6D and DHP-18 dimensions discriminate be-
tween different clinical and/or severity groups as defined
by other indicators. In this study known group validity
was assessed in comparison to groups defined by the
presence or absence of diabetes related and other co-
morbidities at the overall level (i.e. one group reporting
problems and one group reporting no problems) and
also for specific conditions (diabetes problems were feet,
eye and kidney related, and other comorbidities included
arthritis, hypertension, high cholesterol, heart disease
and anxiety/depression). We also used the length of time
with diabetes (as it is a chronic condition where the
HRQL impacts worsen over time, and there is some evi-
dence for differences in PROM scores using this cat-
egory [10]); and diabetes treatment regime (as the
treatment or advised method of control for Type 2 dia-
betes may also be a proxy for severity) as indicators to
assess known group validity. In this case groups were
defined as diet only (least severe), tablets, and insulin
(most severe). Mean scores on the measures, one way
ANOVA significance tests and effect sizes (calculated by
dividing the difference between the mean values for each
group by the standard deviation of the milder severity
group) were used to assess the magnitude and direction
of the differences across the severity groups. Effect sizesof less than 0.2 are considered small, 0.5 moderate, and
0.8 large [21].
Agreement between EQ-5D, SF-6D and DHP-18
dimension scores
Agreement between the measures was investigated using
Bland Altman plots [22]. These charts plot the mean of
a pair of scores on the x axis, and the difference between
the pair of scores on the y axis. This allows agreement
in terms of the difference between the scores to be
assessed across the full severity range, which is done by
adding upper and lower boundaries plus or minus two
standard deviations away from the mean difference in
score on the y axis. Outliers are defined as points out-
side of these boundaries. To allow for an assessment of
the relationship between the utility measures and the the
DHP-18, the dimension scores were rescored on a 0 to 1
scale, and reversed so that a low score was indicative of
increased impairment in line with the GPBMs. This al-
lows for comparison on the same scale which is required
for bland altman plots, and was done for the agreement
analysis only.
Responsiveness
Responsiveness assesses the sensitivity of PROMs to
change in health status over time and is an important
measurement property. Responsiveness was assessed using
the standardised response mean statistic (calculated by
dividing the mean change on the measure by the standard
deviation of the change). SRM categories as defined as fol-
lows: small: >0.2 ≤ 0.5, moderate: >0.5 < 0.8, large: ≥0.8
[22]. Responsiveness was tested for the overall sample,
and also by groups self-reporting improvement, deterior-
ation or no change in their health status. Floor (% at the
lowest level of dysfunctioning) and ceiling effect (% at the
highest degree of dysfunctioning) tests were also carried
out. If a large proportion of the sample is at the floor or
ceiling, the ability of the measure to detect any deterior-
ation or improvement in health status is impaired.
Results
Convergent validity
Correlations between the measures are shown in Table 2.
Negative correlations appear in the table as high score
on an EQ-5D or SF-6D dimension is indicative of poor
health status, but a high score on the utility scale is indi-
cative of better health (i.e. on the full health (1) to dead
(0) utility scale). The same is the case for the DHP-18
dimension scores and the utility scores, where a high
score on the DHP is indicative of lower psychosocial
functioning. Evidence of moderate to strong convergence
between the EQ-5D and SF-6D index and dimension
scores was identified, indicating that both generic measures
are assessing similar constructs. Moderate convergence
Table 2 Convergence between the measures
SF-6D DHP
Index Physical Role Social Pain Mental Vitality PD BA DE
EQ-5D
Index score 0.76 −0.63 −0.55 −0.68 −0.73 −0.45 −0.55 −0.41 −0.43 −0.21
Mobility −0.62 0.63 0.51 0.50 0.62 0.24 0.50 0.21 0.30 0.10
Self care −0.53 0.54 0.40 0.50 0.50 0.24 0.40 0.26 0.35 0.12
Usual activities −0.70 0.67 0.55 0.63 0.63 0.35 0.55 0.30 0.36 0.14
Pain/discomfort −0.65 0.54 0.46 0.53 0.73 0.33 0.49 0.32 0.34 0.17
Anxiety/depression −0.57 0.29 0.53 0.50 0.41 0.65 0.37 0.58 0.443 0.32
DHP
PD −0.46 0.23 0.40 0.41 0.32 0.52 0.32 - - -
BA −0.49 0.34 0.40 0.47 0.37 0.39 0.36 - - -
DE −0.25 0.06 0.22 0.11 0.17 0.28 0.23 - - -
All correlations significant at 0.01 level.
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identified, with the PD dimension correlating highest
with the SF-6D mental health dimension and BA di-
mension correlating highest with the SF-6D index, role
and social scales. This demonstrates overlap between
the constructs being measured on the GPBMS and the
PD and BA dimensions but a range of low correlations
as the GPBM dimension level indicates that the mea-
sures are covering a range of divergent HRQL factors.
However convergence between the GPBMs and the
disinhibited eating factor was on the low side indicating
a lower level of overlap between the constructs.
Known group validity
Table 3 displays the mean scores for the measures across
a range of different clinical and severity groups (with
significant P values in italics). One way ANOVA demon-
strated that the EQ-5D, SF-6D and DHP-18 dimensions
significantly discriminated between patients with and
without diabetes related problems (all p < 0.01), with
effect sizes in the moderate range for all but the DE
dimension. For specific problems, all of the measures
apart from the DHP-18 DE dimension significantly differed
across those with and without foot problems (p < 0.01),
but effect sizes were small. For eye problems, the SF-6D
(p = 0.02) and BA dimension (p < 0.01) were sensitive to
differences with a small effect size. None of the measures
were significantly different across samples with and
without kidney problems, but this is linked to the small
amount of people reporting an issue.
All of the measures also differ across groups with and
without comorbid problems not related to diabetes (all
p < 0.01), with the GPBMs demonstrating large and the
DHP-18 moderate effect sizes. When considering indi-
vidual conditions, the level of differences is more mixed.
Both the GPBMs and the DHP display differences acrossbetween groups defined by the presence or absence of
arthritis and depression/anxiety (all p < 0.01), and the
GPBMS and the DE dimension display significant differ-
ences across groups defined by presence or absence of
heart disease (p < 0.01).
Assessment of scores across groups defined by length
of time with diabetes shows that only the DHP-18 BA
dimension demonstrates significant differences. Both
the GPBMs and the DHP-18 significantly discriminate
based on diabetes treatment regime, but effect sizes
differ both across the measures and between the treat-
ment categories.Agreement between the measures
The Bland Altman plot of EQ-5D and SF-6D (Figure 1)
indicates that agreement was lower where higher levels
of HRQL impairment is reported (outside the lower
boundary), but better at the milder end scale (where the
majority of the values, which are all within the upper
boundary, are found). Agreement between the GPBMS and
the DHP-18 dimension scores is more mixed, with a lower
level of agreement outside across the overall scale of im-
pairment as measured by the instruments (Figures 2 and 3).Responsiveness
EQ-5D and the DHP-18 PD dimension have evidence of
ceiling effects at both baseline and follow up. There was
however, no evidence of a floor or ceiling effect for the
SF-6D or DHP-18 BA and DE dimensions (Table 4).
Overall, responsiveness of the instruments to change in
reported outcome over time was in the range defined as
small. For the health change subgroups it was found that
responsiveness was higher for those self-reporting health
improvement or deterioration which is as would be
expected. However the SRMs were still small.
Table 3 Known group validity of the EQ-5D, SF-6D and DHP-18
Category1 EQ-5D SF-6D DHP-18 (PD) DHP-18 (BA) DHP-18 (DE)
M P ES M P ES M P ES M P ES M P ES
Diabetes related health problems
Overall Yes 0.54 <0.01 0.74 0.63 <0.01 0.66 24.20 <0.01 0.62 28.57 <0.01 0.73 38.11 <0.01 0.16
No 0.73 0.73 13.70 16.80 34.46
Foot related Yes 0.49 <0.01 0.38 0.62 0.01 0.20 26.59 0.02 0.25 30.36 0.04 0.20 39.14 0.32 0.09
No 0.61 0.65 21.15 26.14 37.00
Eye related Yes 0.52 0.12 0.16 0.62 0.02 0.20 25.87 0.09 0.17 30.76 0.01 0.28 39.49 0.15 0.15
No 0.57 0.65 21.97 25.26 36.35
Kidney related Yes 0.57 0.35 0.11 0.65 0.36 0.13 19.90 0.10 0.26 26.23 0.34 0.13 36.10 0.41 0.11
No 0.53 0.63 25.07 28.97 38.60
Comorbid health problems
Overall Yes 0.61 <0.01 1.10 0.67 <0.01 1.17 19.73 <0.01 0.70 22.92 <0.01 0.55 37.66 <0.01 0.43
No 0.84 0.81 9.86 14.54 28.27
Arthritis Yes 0.48 <0.01 1.08 0.61 <0.01 1.08 22.00 <0.01 0.24 26.39 <0.01 0.42 38.90 0.08 0.11
No 0.76 0.73 17.12 19.00 36.31
Hypertension Yes 0.62 0.64 0.03 0.67 0.52 0.07 19.69 0.96 0.00 23.37 0.46 0.05 38.13 0.52 0.04
No 0.61 0.66 19.75 22.42 37.16
High cholesterol Yes 0.61 0.90 0.00 0.67 0.35 0.06 19.69 0.96 0.00 23.33 0.43 0.00 38.12 0.45 0.05
No 0.61 0.66 19.76 22.28 36.97
Heart disease Yes 0.48 <0.01 0.47 0.61 <0.01 0.40 18.76 0.63 0.05 25.34 0.18 0.14 32.32 0.01 0.26
No 0.63 0.67 19.84 22.63 38.37
Anxiety/depression Yes 0.45 <0.01 0.70 0.57 <0.01 0.75 34.12 <0.01 1.02 31.30 <0.01 0.59 46.72 <0.01 0.53
No 0.66 0.69 15.69 20.57 35.14
Length of time diagnosed < 5 years 0.66 0.41 0.06 0.70 0.08 0.13 17.18 0.18 0.08 18.52 <0.01 0.35 35.92 0.91 0.01
> = 5 years 0.64 0.68 18.82 24.77 35.76
Treatment regime Diet 0.69 <0.01 0.10 0.71 <0.01 0.06 12.76 <0.01 0.36 14.49 <0.01 0.52 32.75 0.01 0.17
Tablets 0.66 0.42 0.70 0.44 18.62 0.29 22.04 0.65 36.81 0.08
Insulin 0.53 0.63 24.58 34.49 38.59
1The sample sizes for each category are included in Table 1.
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This study reports on the psychometric assessment of
the relationship between the genericEQ-5D and SF-6D
and the condition specific DHP-18 for use with Type 2
diabetes. The study provided supporting evidence for the
construct validity of all three measures, as we found that
the measures discriminate between groups with differing
levels of health problems and diabetes specific issues.
This is in line with previous findings regarding their psy-
chometric properties in diabetes samples [8,10,11]. How-
ever the results need to be interpreted with caution due
to the indicators used, where the GPBMs may be sensi-
tive to the co-morbid problems being reported rather
than diabetes-related HRQL factors per se. It is also in-
teresting to note that the DHP-18 discriminates between
groups defined by presence or absence of non-diabetes
specific co-morbid conditions. This could be linked tothe progressive nature of diabetes, where co morbid
health problems are more likely to be present when the
impacts of diabetes are more severe. There was also evi-
dence that the instruments measure overlapping con-
structs relevant in Type 2 diabetes to some extent, but
there is still clear divergence and evidence of disagree-
ment between the GPBMs and the DHP-18 across the
severity scale. Further evidence about the responsiveness
of the measures is required.
The results support the use of both the condition spe-
cific DHP-18 and EQ-5D and SF-6D in studies requiring
the assessment of HRQL and psychosocial functioning
in diabetes and there is evidence that using both a gen-
eric and condition specific measure will provide a more
holistic assessment of the HRQL impacts of diabetes and
related treatments. This is because the measures have
some level of sensitivity to diabetes specific health
Figure 1 Agreement between EQ-5D and SF-6D.
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of the constructs measured which are of relevance to
people with diabetes. However there is also clear diver-
gence observed at the dimension level, where a range of
areas of HRQL are assessed. Therefore the use of the
measures alongside each other may increase the accuracy
of outcomes assessment in Type 2 diabetes by enabling
the measurement of generic health concerns alongside
diabetes specific indicators. This is because the GPBMs
may allow for a wider assessment of HRQL.
With regard to responsiveness, both the EQ-5D and
SF-6D perform better in the groups who self-report
health change, although all three measures had low
SRMs indicating a generally low level of responsiveness.Figure 2 Agreement between EQ-5D and DHP-18 dimension scores.This low level of sensitivity could be problematic in the
assessment of change in QALYs before and after inter-
ventions. However, this finding could be due to the study
design and sample used, which was not testing a specific
intervention, but was a population survey testing a
change in service structure, where health may not be
expected to change for all respondents between baseline
and follow up. Secondly, the measure of change used
was a self-report generic question which may not have a
strong relationship with changes on generic or diabetes
specific PROMs. It may be important to investigate re-
sponsiveness in more detail using diabetes specific indi-
cators of health change. Recently, a five level version of
EQ-5D (EQ-5D-5L) [23] has been developed, and this
Figure 3 Agreement between SF-6D and DHP-18 dimension scores.
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over time. However direct utility values for EQ-5D-5L
are not yet available.
Another key finding of this work is the strong relation-
ship between the EQ-5D and SF-6D which has been




Overall 0 0 23.3
Health improvement 0 0 27.6
No change 0 0 28.7
Health deterioration 0 0 6.2
SF-6D
Overall 0 0 2.9
Health improvement 0 0 4.3
No change 0 0 3.5
Health deterioration 0 0 0.4
DHP-18 (PD)
Overall 0.2 0.4 29.0
Health improvement 0 0 27.0
No change 0 0.3 33.3
Health deterioration 0.8 1.2 19.3
DHP-18 (BA)
Overall 0.3 0.2 13.7
Health improvement 0 0 15.2
No change 0 0.1 15.7
Health deterioration 0 0.4 7.4
DHP-18 (DE)
Overall 1.3 1.0 5.3
Health improvement 0.5 0 5.5
No change 1.3 0.7 5.2
Health deterioration 1.9 2.8 5.4across other health conditions [24]. The utility values de-
rived from the measures were similar, but due to
differences in the range of the utility scale (where SF-6D
has a much smaller range) the spread of values differed.
This affects agreement at the more severe end of the
utility scale, where less SF-6D values are available, andtus
% at ceiling Mean (sd) change SRM
T1
23.2 −0.01 (0.23) −0.04
31.0 0.04 (0.22) 0.18
28.6 −0.01 (0.20) −0.05
2.8 −0.07 (0.29) −0.24
1.8 −0.01 (0.11) −0.09
2.8 0.03 (0.12) 0.25
2.3 −0.01 (0.10) −0.10
1.2 −0.03 (0.11) −0.27
28.5 −0.28 (14.66) −0.02
26.4 −1.91 (14.87) −0.13
32.5 −0.36 (13.62) −0.03
18.0 0.86 (16.08) 0.05
13.4 0.52 (13.95) 0.04
15.4 −2.74 (13.96) −0.20
15.1 0.46 (12.59) 0.04
7.6 2.83 (17.01) 0.17
6.2 −0.48 (16.25) −0.03
6.6 −4.25 (18.57) −0.23
6.4 −0.10 (15.33) −0.01
4.4 1.08 (16.71) 0.06
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[25]. The utility scales were well correlated and at the di-
mension level, the correlations across similar dimensions
indicates overlap in the constructs being measured. Both
GPBMs also displayed evidence of distinguishing be-
tween clinical and severity groups. This means that both
measures have a level of validity for use in Type 2
diabetes, and the values from both instruments could be
used in the estimation of QALYs with some confidence.
The overlap between the measures means that there is
not the requirement to include both in surveys, and
there are advantages and disadvantages to both. EQ-5D
is short and easy to complete, and is accepted by NICE
for use in the economic evaluation of interventions.
The SF-6D is derived from the SF-36 or SF-12, and
therefore requires this to be included, but these
measures also provide detailed information about the
HRQL of patient samples.
There are a number of limitations to this study which
should be considered when interpreting the findings.
Firstly, psychometric validity is difficult to prove as there
is no gold standard for the measurement of outcomes
against which to compare the measures. Therefore valid-
ity can only be inferred against other indicators and
across the instruments. Secondly, the findings are lim-
ited to the sample used which has specific characteristics
which may impact on findings, particularly in relation to
the level of responsiveness that should be expected in a
population survey. Further work should be done to test
the validity and responsiveness of EQ-5D, SF-6D and
DHP-18 in relation to other diabetes specific PROMS
and clinical indicators using a range of patient samples
(including clinical trials to assess responsiveness in more
detail). This strategy has been used in the assessment of
the EQ-5D and SF-6D across mental health conditions
[26]. Psychometric evidence is one method of assessing
validity, and should be considered alongside other evi-
dence to build up a picture of the measures performance.
This study complements an earlier systematic review that
found support for the construct validity of EQ-5D [10].
Qualitative work could also be used to assess whether all
of the HRQL issues of importance to people with diabetes
are assessed by the PROMS that are used for the condi-
tion (see, for example Brazier et al. [27] who used this ap-
proach in mental health. Finally, the results are limited to
Type 2 diabetes, and further assessment of the GPBMs
and Type 1 diabetes specific PROMs is warranted.
Conclusion
The psychometric assessment of the relationship be-
tween the EQ-5D, SF-6D and DHP-18 shows that all
have a level of validity for use in Type 2 diabetes, and
suggests that the measures can be used alongside each
other to provide a more holistic assessment of theHRQL issues that are important to people with Type 2
diabetes. We recommend that both generic and condi-
tion specific measures are used to assess health status
in diabetes.
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